Latest news and press releases about Alector, Inc. (ALEC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
Price
| Price | $1.93 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -18.68 |
| EV / EBITDA | -1.95 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -531.04% |
| Return on Invested Capital | -67.56% |
| Return on Assets | -58.10% |
| Gross Margin | -360.92% |
| Operating Margin | -914.56% |
| Net Margin | -850.13% |
Related companies: ABOS · APLT · CRBP · FATE · IRD · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ALEC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks